NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE66398 Query DataSets for GSE66398
Status Public on Oct 06, 2015
Title Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer [copy number]
Organism Homo sapiens
Experiment type Genome variation profiling by SNP array
Summary The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate as compared to chemotherapy plus either trastuzumab or lapatinib. An extensive biomarker programme was prospectively planned to identify potential predictors of sensitivity to different treatments and evaluate treatment effect on tumor biomarkers.
A mutation in PIK3CA exon 20 or 9 was documented in 20% of the cases. Overall, the pCR rates were similar in PIK3CA wild type and PIK3CA mutated patients (33.3% vs 22.7%; p=0.323). However, for patients receiving trastuzumab plus lapatinib, the probability of pCR was higher in PIK3CA wild type tumors (48.4% vs 12.5%; p=0.06). Ki67, pAKT and apoptosis measured on the residual disease were significantly reduced from baseline. The degree of Ki67 inhibition was significantly higher in patients receiving the dual anti-HER2 blockade. In conclusion, PIK3CA mutations seem to identify patients less likely to benefit from dual anti-HER2 inhibition. p95-HER2 and markers of PI3K pathway deregulation are not confirmed as markers of different sensitivity to trastuzumab or lapatinib.
 
Overall design 121 HER2-positive breast cancer patients were randomly assigned to neoadjuvant chemotherapy plus either trastuzumab, lapatinib or both trastuzumab and lapatinib. Pre-treatment, fresh-frozen tissue samples were collected for genomic analyses. 69 samples passed quality control for DNA and were profiled for copy number with Affymetrix technology using the Genome-Wide Human SNP 6.0 Array.
 
Contributor(s) Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P
Citation(s) 26245675
Submission date Feb 27, 2015
Last update date Nov 27, 2018
Contact name Enrico Tagliafico
E-mail(s) enrico.tagliafico@unimore.it
Organization name University of Modena and Reggio Emilia
Department Center for Genome Research
Street address Via Campi 287
City Modena
State/province MO
ZIP/Postal code 41126
Country Italy
 
Platforms (1)
GPL6801 [GenomeWideSNP_6] Affymetrix Genome-Wide Human SNP 6.0 Array
Samples (68)
GSM1621442 sample_01-AG-015 [copy number]
GSM1621443 sample_01-AV-013 [copy number]
GSM1621444 sample_01-CB-007 [copy number]
This SubSeries is part of SuperSeries:
GSE66399 Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer
Relations
BioProject PRJNA276845

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE66398_CHERLOB_log2Ratio_chr1.txt.gz 45.0 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr10.txt.gz 28.8 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr11.txt.gz 27.6 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr12.txt.gz 26.9 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr13.txt.gz 20.5 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr14.txt.gz 17.6 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr15.txt.gz 16.5 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr16.txt.gz 16.6 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr17.txt.gz 14.3 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr18.txt.gz 16.1 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr19.txt.gz 9.3 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr2.txt.gz 47.4 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr20.txt.gz 13.3 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr21.txt.gz 7.7 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr22.txt.gz 7.4 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr3.txt.gz 39.5 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr4.txt.gz 37.1 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr5.txt.gz 35.8 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr6.txt.gz 34.8 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr7.txt.gz 31.0 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr8.txt.gz 30.2 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chr9.txt.gz 25.2 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chrX.txt.gz 26.8 Mb (ftp)(http) TXT
GSE66398_CHERLOB_log2Ratio_chrY.txt.gz 2.4 Mb (ftp)(http) TXT
GSE66398_RAW.tar 4.2 Gb (http)(custom) TAR (of CEL, CNCHP)
Processed data included within Sample table
Processed data provided as supplementary file
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap